Ovarian Cancer

Rubraca Approved as Maintenance Treatment for Recurrent Ovarian Cancer

By April 06, 2018

The new approval was based on data from the Phase 3 ARIEL3 clinical trial (N=564).

FDA Approves New Indication, Formulation for Lynparza

By August 18, 2017

The approvals were based on two, placebo-controlled trials (SOLO-2, Study 19) in patients with recurrent ovarian cancers who were in response to platinum-based therapy.